Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Single-Dose, Randomized, Open-Label, Active-Controlled, Crossover, Pharmacodynamic, and Pharmacokinetic Comparative Study of a Novel Pramlintide-Insulin Co-Formulation in Adults With Type 1 Diabetes Mellitus

Next Previous
Search
Trial Profile

A Phase 2, Single-Dose, Randomized, Open-Label, Active-Controlled, Crossover, Pharmacodynamic, and Pharmacokinetic Comparative Study of a Novel Pramlintide-Insulin Co-Formulation in Adults With Type 1 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin/pramlintide (Primary) ; Insulin; Pramlintide
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors XERIS Pharmaceuticals

    • Most Recent Events

    • 23 Mar 2021 Results presented at the 103rd Annual Meeting of the Endocrine Society
    • 18 Jun 2020 According to a Xeris Pharmaceuticals media release, an end-of-phase 2 meeting with the FDA is anticipated later this year.
    • 18 Jun 2020 Results published in the Xeris Pharmaceuticals media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top